Rachel Brathwaite
ID:
|
Assessing the Feasibility of Economic Approaches to Prevention of Substance
Abuse among Adolescents
REFNo: HS2683ES
Aim 1. Examine the prevalence and consequences of ADU in a cohort of 200 AYLHIV (ages 18-24) seen at six (6) HIV clinics in southwestern Uganda.
Aim 2. Using a mixed methods approach, identify the multi-level (individual, interpersonal, community and structural) factors associated with ADU among AYLHIV.
Aim 3. Using a subset of the sample, explore the feasibility and short-term effects of a family-based economic empowerment intervention on ADU among AYLHIV.
|
Masaka,
|
Trinidad and Tobago |
2023-03-02 15:32:31 |
2026-03-02 |
230 |
220 Adolescents and youths living with HIV aged 18-24 years. 10 healthcare providers aged >18 years. |
National Institute on Alcohol Abuse and Alcoholism |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Fred Bulamba
ID: UNCST-2020-R014888
|
PErioperative respiratory care and outcomes for patieNts Undergoing hIgh risk abdomiNal surgery
REFNo: HS2178ES
To explore the cost-effectiveness of the different treatment combinations in reducing pneumonia and SSI at pre-selected centres.,To assess the impact of both interventions on postoperative mortality at 30-days, and the effect of 80-100% FiO2 only on the re-operation rate at 30 days after surgery.,To assess whether (1) preoperative 0.2% chlorhexidine mouthwash reduces the rate of postoperative pneumonia at 30-days compared to no mouthwash, and (2) 80-100% FiO2 used during surgery reduces the rate of postoperative SSI at 30-days compared to 21-35% FiO2, amongst patients aged 10 years or over undergoing elective or emergency midline laparotomy, with an anticipated abdominal incision of ≥5cm, for any indication except caesarean section.,
|
Mbale, Hospital cell
|
Uganda |
2025-08-28 10:15:49 |
2028-08-28 |
1000 (for Uganda only) |
Patients above 10 years undergoing abdominal surgery |
Dr Birgit Whitman |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Eugene Ruzagira
ID: UNCST-2023-R008282
|
A phase Ib study to assess the safety and immunogenicity of a recombinant adenovirus-based vaccine against plague in Uganda
REFNo: HS2387ES
Primary
To investigate safety and tolerability of 5 x 1010 VP of the proposed ChAdOx1 Plague vaccine in healthy African adults aged 18 to 49 residing in Uganda, when given as one or two dose(s) intramuscularly with different prime-boost intervals
Secondary
To determine the immunogenicity of 5 x 1010 VP of the proposed ChAdOx1 Plague vaccine, in healthy African adults aged 18 to 49 years residing in Uganda when given as one or two dose(s) intramuscularly with different prime-boost intervals.
Tertiary
Exploratory immunogenicity assays to determine the immunogenicity of 5 x 1010 VP of the proposed ChAdOx1 Plague vaccine, in healthy African adults aged 18 to 49 years residing in Uganda when given as one or two dose(s) intramuscularly with different prime-boost intervals.
|
Masaka, KATWE
|
Uganda |
2022-09-12 18:28:42 |
2025-09-12 |
36 |
Healthy male or female African adults aged 18-49 years, inclusive. Inclusion and exclusion criteria are as follows:
Inclusion Criteria
• Willing and able to give informed consent for participation in the trial.
• Male or female aged between 18-49 years inclusive at enrolment (first vaccination visit, V1)
• In good health as determined by
o Medical history (as determined by verbal medical history)
o Physical examination
o Clinical judgment of the investigators
• Female participants of childbearing potential must be willing to ensure that they use effective contraception during the trial and for 3 months after the last vaccination.
• Female participants of childbearing potential must have a negative pregnancy test on the day(s) of screening and vaccination.
• Able to attend the scheduled visits and to comply with all study procedures
• Agrees to refrain from donating blood for the duration of the trial
• Clinically acceptable baseline screening results (includes vital signs, physical examination, urinalysis, and laboratory results)
• In the Investigator’s opinion, is able and willing to comply with all trial requirements.
Exclusion Criteria
The participant may not be enrolled in the study if any of the following apply:
• Female participant who is pregnant, lactating or planning pregnancy during the course of the trial.
• History of significant organ/system disease that could interfere with trial conduct or completion. This includes a known history of significant disease in the following:
o Cardiovascular disease including congenital heart disease, previous myocardial infarction, valvular heart disease (or history of rheumatic fever), previous bacterial endocarditis, history of cardiac surgery (including pacemaker insertion), personal or family history of cardiomyopathy or sudden adult death
o Respiratory disease such as uncontrolled asthma and chronic obstructive pulmonary disease
o Endocrine disorders such as diabetes mellitus and Addison’s disease
o Significant renal or bladder disease
o Biliary tract disease
o Gastro-intestinal disease such as inflammatory bowel disease, major abdominal surgery within the last two years, coeliac disease and liver disease (including hepatitis B or C infection)
o Neurological disease such as seizures and myasthenia gravis
o Haematological problems such as coagulation problems or anaemia (haemoglobin < 12.5g/dL for females and < 13.5 g/dL and for males)
o Metabolic disease such as glucose-6-phosphate dehydrogenase deficiency
o Psychiatric illness requiring hospitalisation or depression if severity is deemed clinically significant by the study Investigators
o Known or suspected drug and/or alcohol misuse
o Non-benign cancer, except squamous cell or basal cell carcinoma of the skin and cervical carcinoma in situ
• Any other significant disease or disorder which, in the opinion of the Investigator, could:
o Put the participant at risk because of participation in the trial
o Influence the result of the trial
o Impair the participant’s ability to participate in the trial
• History of allergy to a vaccine or any component of the vaccines used in this study
• History of anaphylaxis
• Have any known or suspected impairment or alteration of immune function, resulting from, for example:
o Congenital or acquired immunodeficiency
o Human Immunodeficiency Virus infection or symptoms/signs suggestive of an HIV-associated condition
o Autoimmune disease
o Receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 12 months or long-term systemic corticosteroid therapy (including for more than 7 days consecutively within the previous 3 months).
• Receipt of immunoglobulins or any blood product transfusion within 3 months prior to enrolment
• Scheduled elective surgery or other procedures requiring general anaesthesia during the trial
• Weight <50kg or a body mass index (BMI) greater than 35kg/m2.
• Known history of previous occurrence of disease caused by Y. pestis or receipt of a vaccine against plague
• Current active participation in another research study involving an investigational product (including receipt of an IMP within last 30 days) or where involvement in this study could impact the results
• It is not in the best interest of the volunteer to participate in the trial, in the opinion of the Investigator.
|
University of Oxford |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Yerusa Kiirya
ID:
|
Acceptability, Feasibility and Effectiveness of a WhatsApp peer support group as a strategy to improve antiretroviral therapy adherence among youth in Kampala District
REFNo: SIR170ES
To determine the effectiveness of a WhatsApp peer support group combined with the standard of care in improving ART adherence among YLHIVA aged 15-24 years in Kampala district.,To determine the effect of a WhatsApp peer support group combined with the standard of care on psychosocial barriers to ART adherence and retention in care among YLHIVA aged 15-24 years in Kampala district.,To assess the feasibility of using a WhatsApp peer support group combined with the standard of care as an ART adherence and retention in care strategy among YLHIVA aged 15-24 years, To asses the acceptability of a WhatsApp peer support group combined with the standard of care as an ART adherence and retention in care strategy among YLHIVA aged 15-24 in Kampala district.,To assess the acceptability, feasibility and effectiveness of a WhatsApp peer support group combined with current standard care as a strategy to improve ART adherence among YLHIVA in Kampala.,
|
Kampala, Kiswa
Kampala, Komambogo
Kampala, Kawala
|
Uganda |
2023-01-20 14:23:51 |
2026-01-20 |
488 |
This study will be conducted among YLHIVA aged 15-24 years currently receiving ART services at
Kiswa, Komambogo and Kawala HCIII with an
ART adherence score of less than 95% within the past 12 months |
Strengthening behavioral and social science research capacity to address evolving challenges in HIV care and prevention in Uganda. |
Engineering and Technology |
Clinical Trial |
Degree Award |
|
Irene Andia Biraro Rebecca
ID: UNCST-2019-R001475
|
A Randomized Double Blind Placebo Controlled Trial of Rifapentine and Isoniazid for Prevention of Tuberculosis in People with Diabetes.
REFNo: HS1112ES
Primary objective:
To assess the efficacy of preventive therapy with a 12-week course of rifapentine and isoniazid (3HP) against the development of probable or definite TB disease over 24 months in people with Diabetes Mellitus (DM) who are latent TB infection (LTBI) test positive.
Secondary objectives:
• To assess the efficacy of 3HP against the development of possible, probable or definite TB disease over 24-40 months in people with DM who are latent tuberculosis infection test positive
• To compare the proportions who complete treatment between arms
• To compare the occurrence of adverse events between arms
• To compare the rate of TB or death between arms
• To compare the overall mortality rate between arms
• To explore the efficacy of 3HP against development of probable or definite TB in those who are LTBI test positive, across the following sub-groups, separately: study site (n=3); age groups; duration of DM; level of glycaemic control (baseline HbA1C) and body mass index (BMI).
• To assess the efficacy of 3HP against development of probable or definite TB, in two restricted analyses: TST positive and IGRA positive participants.
• To carry out sub-studies including i) an economic modelling and cost effectiveness study, ii) a cohort study of those who are IGRA and TST negative a baseline, iii) a cross-sectional study of HIV and TB prevalence and DM phenotype, (iv) evaluation of point-of care (POC) testing for LTBI, and computer-assisted X-ray, (v) a public health study of patient management, and v) future genetic studies.
|
Kampala, Munyonyo
Wakiso, Kasangati
Kampala, Rubaga
|
Uganda |
2021-06-18 |
2024-06-18 |
1500 |
Inclusion criteria
I. Enrolled in diabetes care with a history of DM and current use of anti-diabetic medication (‘known DM’); OR in the absence of anti-diabetic medication an HbA1c of ≥6.5% (48 mmol/mol) or a fasting venous plasma glucose of ≥7. |
National Institute for Medical Research, Mbeya Tanzania |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Haruna Muwonge
ID: UNCST-2019-R000128
|
A Randomized, Double-Blinded, Placebo-Controlled, Phase III, Clinical Trial of SARS-CoV-2 Vaccine, Inactivated (Vero Cell) in Adults Aged 18 Years and Above
REFNo: HS2185ES
Safety: To evaluate adverse events from the first dose and the booster dose to Day 28 after the whole-course immunization and serious adverse events from the first dose and the booster dose to at least 12 months after the whole-course immunization,Efficacy: To evaluate the efficacy of the SARS-CoV-2 Vaccine, Inactivated (Vero Cell) for symptomatic and laboratory-confirmed (RT-PCR method) COVID-19 cases caused by different SARS-CoV-2 variants,Immunogenicity: To evaluate the immune persistence of the investigational vaccine,Immunogenicity: To demonstrate the consistency of 3 lots of investigational vaccine in terms of GMT 14 days after the whole-course immunization,Immunogenicity: To evaluate the levels of neutralizing antibody and IgG antibody against SARS-CoV-2 14 days after the whole-course and after the booster immunization,Efficacy: To evaluate the efficacy of the SARS?CoV?2 Vaccine, Inactivated (Vero Cell) against symptomatic and laboratory-confirmed (RT?PCR method) severe COVID-19 disease,Efficacy: To evaluate the efficacy of the SARS?CoV?2 Vaccine, Inactivated (Vero Cell) after at least one dose, 2 doses, and after the booster dose of immunization,To evaluate the efficacy, safety and immunogenicity of the SARS?CoV?2 Vaccine, Inactivated (Vero Cell) in adults aged 18 years and above after a 2-dose schedule, and after booster vaccination,
|
Kayunga, Ntenjeru
Jinja, Nakasero
Mityana, Central Ward
Mubende, Kyaterekera
Gulu, Agwee
Wakiso, Central Ward
Mukono, Ggulu Ward
Kampala, Mulago I
|
Uganda |
2022-04-07 |
2025-04-07 |
5000 |
Adults 18years and above, male and female, all tribes that fulfill the study inclusion criteria |
Institute of Medical Biology Chinese Academy of Medical Sciences |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
David Lubogo
ID: UNCST-2020-R014473
|
Metabolic Syndrome among Females of Reproductive age in Wakiso district, Central Uganda: Risk factors and Effectiveness of a Community based Nutrition Education Intervention
REFNo: HS1281ES
General objective: To investigate the prevalence of, and factors associated with metabolic syndrome (MetS) and evaluate the effect of a community based nutrition education intervention among females of reproductive age with MetS in Wakiso district, Central Uganda in order to contribute information for the design of interventions for MetS.
Specific objectives
1. To determine the prevalence of, and factors associated with Metabolic Syndrome.
2. To determine optimal WC cut off points for MetS.
3. To determine the effectiveness of a 12 -week community-based nutrition education and counseling intervention for metabolic syndrome on selected cardiovascular outcomes (BP), biochemical outcomes (HDL, TGS, blood sugar), anthropometric measures (WC, weight), behavioral outcomes (dietary intake, physical activity), and on knowledge as an outcome.
4. To explore the female and health care provider perceptions/perspectives towards the nutrition promotion intervention on MetS among female of reproductive age in South Central Uganda.
|
Wakiso,
Wakiso,
|
Uganda |
2021-12-28 |
2024-12-28 |
840 |
Females aged 15- 49 years in Wakiso district. |
Strengthening Education and Training Capacity in Sexual and Reproductive Health and Rights in Uganda (SET-SRHR) and the Government of Uganda |
Medical and Health Sciences |
Clinical Trial |
Degree Award |
|
Achilles Katamba
ID: UNCST-2019-R000540
|
Clinic versus Hotspot Active Case Finding and Linkage to TB Preventive Therapy (ACF/TPT) Strategy Evaluation for Tuberculosis
REFNo: HS2166ES
3. To estimate (using simulation) the impact of each intervention on diagnostic delays and TB prevalence.,2. To measure the implementation of hotspot-based and facility-based ACF + TPT, including the reach (number of individuals willing to be screened), implementation (measured via cascades of care), and maintenance (of effectiveness over time).,1. To compare the effectiveness of hotspot-focused versus facility-based ACF + linkage to TPT in terms of the number of individuals started on treatment for microbiologically confirmed TB in each community (i.e., reduction in undiagnosed TB prevalence, primary outcome) ,
|
Lwengo,
Masaka, Kalisizo
Mpigi, Nkozi
Mityana, Mityana
Bugiri, Bugiri
Butambala, Gombe
Iganga, Iganga
Kiboga, Kiboga
Lyantonde, Lyantonde
Mukono, Mukono
Kayunga, Kayunga
Luweero, Luwero
Mubende, Kassanda
Jinja, Kawoolo
Buikwe, Kawolo
Nakaseke, Nakaseke
|
Uganda |
2022-05-18 9:43:01 |
2025-05-18 |
80000 |
All willing participants 15 years and above of any sex and tribe residing with the study area |
National Institutes of Health |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Pontiano Kaleebu
ID: UNCST-2021-R013577
|
An open label, Phase 2 study to evaluate the safety and immunogenicity of an Ad26.ZEBOV booster dose in Human Immunodeficiency Virus Positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen
REFNo: HS1350ES
• To assess the safety and tolerability of a Ad26.ZEBOV booster dose in HIV positive adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen.
• To assess humoral responses induced by the booster dose against EBOV glycoprotein (GP), as measured by Filovirus Animal Non-Clinical Group (FANG) Enzyme-Linked Immunosorbent Assay (ELISA) at 7 and 21 days.
|
Masaka, NOT APPLICABLE
Lwengo, NOT APPLICABLE
Bukomansimbi, NOT APPLICABLE
Kalungu, NOT APPLICABLE
|
Uganda |
2021-08-04 |
2024-08-04 |
50 participants |
Participants must be healthy (based on physical examination, medical history, and clinical judgment) HIV positive adults who received the Ad26.ZEBOV and MVA-BN-Filo vaccine regimen in the VAC52150EBL2002 trial and were aged ≥18 to ≤50 years at the tim |
London School of Hygiene & Tropical Medicine |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Maxensia owor
ID: UNCST-2021-R014003
|
IMPAACT 2017: Phase I/II Study of the Safety, Acceptability, Tolerability, and Pharmacokinetics of Oral and Long-Acting Injectable Cabotegravir and Long-Acting Injectable Rilpivirine in Virologically Suppressed HIV-Infected Children and Adolescents. Version 3.0, dated 13 August 2020
REFNo: HS1356ES
Primary Objectives:
Cohort 1
1.To confirm the doses for oral CAB followed by injectable CAB LA in HIV-infected, virologically suppressed adolescents
2.To confirm doses for injectable RPV LA in HIV-infected, virologically suppressed adolescents by evaluating safety and multiple dose PK of RPV LA through Week 16
Cohort 2:
1.To assess the safety of CAB LA + RPV LA through Week 24 in HIV-infected, virologically suppressed adolescents
Secondary Objectives: Cohort 1
• To monitor maintenance of viral suppression through Week 16 in HIV-infected, virologically suppressed adolescents
• To evaluate the tolerability and acceptability of CAB LA through Week 16 in HIV-infected,virologically suppressed adolescents
• To evaluate the tolerability and acceptability of RPV LA through Week 16 in HIV-infected,virologically suppressed adolescents
Secondary Objectives: Cohort 2
• To assess safety of oral CAB + oral RPV followed by CAB LA + RPV LA through Week 48 in HIVinfected, virologically suppressed adolescents
• To evaluate repeat-dose pharmacokinetics of CAB LA + RPV LA through Week 24, and through
Week 48 in HIV-infected, virologically suppressed adolescents.
• To assess antiviral activity of CAB LA + RPV
|
Kampala, Mulago
Kampala, Mulago 1
|
Uganda |
2021-08-11 |
2024-08-11 |
155 participants overall but MUJHU plans to enroll 18-25 participants |
HIVâ€1 infected children and adolescents, 12 to <18 years of age, who are
virologically suppressed on stable cART consisting of 2 or more drugs from 2 or
more classes of antiretroviral drugs, |
National Institutes Of Health |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Ronald Kiguba
ID: UNCST-2019-R000844
|
Two-way risk communication mobile application use versus traditional methods of adverse drug reaction reporting in Uganda: a cluster-randomized controlled trial
REFNo: HS1366ES
This study will: i) assess the feasibility of implementing a mobile app for the reporting of ADRs associated with DTG and IPT at selected ART-sites in Uganda; ii) describe the characteristics (causality, seriousness, completeness, unexpectedness, severity, outcome) of the DTG- and IPT-linked ADR-reports submitted to NPC using the mobile app; and, iii) determine if use of the mobile app versus existing methods of ADR-reporting (paper-form and web-form) increases by 25% the number of reported ADRs linked to DTG and IPT use during 2.5 years of follow-up, iv) determine the cost and cost-effectiveness of using the mobile app versus existing methods of ADR-reporting.
|
Wakiso, Seguku
|
Uganda |
2021-08-20 |
2024-08-20 |
382 Antiretroviral Sites across Uganda |
The mobile app will be introduced nationwide at 382 high-volume accredited antiretroviral therapy (ART)-sites where MoH implemented the scale up of IPT. These pre-selected ART-sites hold 80% of the patients on ART in Uganda. All HCPs at the pre-selected A |
Makerere University Research & Innovations Fund |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Deborah Ojiambo
ID:
|
Efficacy of Group Activity Adherence Counselling (GAAC) for Adolescents with Unsuppressed HIV viral load at three large HIV clinics in Uganda: Randomized controlled trial
REFNo: SS805ES
1.To examine the barriers such as behavior problems and mental health problems to adherence experienced by adolescents living with HIV.
2.To evaluate the efficacy of GAAC in addressing barriers to adherence among adolescents living with HIV.
3.To assess whether GAAC is associated with viral load suppression, among adolescents living with HIV compared to Standard Service Provision (SSP)
|
Kampala, Mulago 1
Wakiso, Entebbe
|
Uganda |
2021-07-07 |
2024-07-07 |
300 |
The population for this study is school-going adolescents living with HIV (12-18 years) who received ART for at least 6 or more months at Mulago ISS, TASO Mulago, TASO Entebbe HIV clinics |
Makerere University Research and Innovation Fund (RIF) funded by Uganda government |
Social Science and Humanities |
Clinical Trial |
Non-degree Award |
|
Musa Sekikubo
ID: UNCST-2021-R014010
|
A multi-Centre, randomised, placebo controlled, double-blind, parallel group study to evaluate the safety, tolerability and immunogenicity of two doses of Group B Streptococcus vaccine (GBS-NN/NN2) in women who are pregnant and living with HIV and women who are pregnant and do not have HIV
REFNo: HS1390ES
Objectives
Primary Objectives:
Safety:
To evaluate the safety and tolerability of the GBS-NN/NN2 vaccine in women living with HIV and women without HIV and their newborn babies from vaccination up to delivery/birth.
Immunological:
To compare the transfer rate of vaccine- specific immunoglobulin G (IgG) antibody concentrations from the mother to the baby at birth in women living with HIV with the transfer rate in women without HIV. This endpoint will be used to determine the sample size calculation.
Secondary Objectives
Safety: The safety and tolerability of the GBS-NN/NN2 vaccine in the mother and baby over the first 6 months post-partum, as assessed at 6 months of age.
Immunological: The secondary immunological objectives are:
• To compare IgG antibody responses, specific to the GBS-NN/NN2 vaccine, induced by the first and second vaccine doses over time in pregnant women living with HIV and pregnant women without HIV.
• To evaluate the concentration of IgG antibodies specific for the GBS-NN/NN2 vaccine up to 6 months post-delivery in the mother and baby in women with and without HIV.
• To determine the concentrations of vaccine specific IgG to GBS-NN/NN2 in cord blood at delivery in babies born to women with and without HIV.
Exploratory Objectives
• To compare between groups the isotype composition of the vaccine specific antibodies; in particular IgG and IgA as well as their subclasses, i.e. IgG1-4, IgA1 and IgA2 in maternal and cord blood.
• To compare between groups the vaccine specific IgG antibodies to Rib, Alp1, Alp2 and AlpC, GBS-NN and GBS-NN2 in maternal and cord blood.
• To compare between groups the functional activity of vaccine specific antibodies from cord blood in an opsonophagocytic killing assay (OPkA) and other in vitro assays in selected samples.
|
Kampala, Kawempe
|
Uganda |
2021-06-08 |
2024-06-08 |
50 |
HIV negative and HIV positive pregnant women aged 18 to 40 years attending Kawempe national referral Hospital |
MINERVAX AS |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Susan Nabadda
ID: UNCST-2020-R014331
|
Diabetes Mellitus Tuberculosis and HIV multimorbidities among adult patients attending Kiruddu National Referral Hospital, Uganda
Version 2 7/26/2020.
REFNo: HS1386ES
General Objective
The overall objective of this project is to determine the prevalence of DM among patients with either TB, HIV, and TB-HIV co morbidity. This will help to assess the prevalence of silent DM in these categories of patients.
Specific objectives
1. To describe the prevalence of DM among either TB patients or HIV patients or patients with both TB and HIV co morbidity attending the Kiruddu hospital outpatient clinics
2. To determine the factors associated with DM in patients with HIV alone, TB alone and HIV – TB co-infection.
|
Kampala, Buziga
|
Uganda |
2021-06-29 |
2024-06-29 |
1000 |
Adults of 18 years and above, HIV-infected patients or TB patients receiving care at Kiruddu National Referral Hospital (patients with both TB and HIV will also be included)
However, patients who will be critically ill and in need of emergency clinical c |
Beckton Dickinson and the United States Centers for Disease Control and Prevention (CDC), Uganda. |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
JUSTUS BARAGEINE KAFUNJO
ID: UNCST-2020-R014150
|
COMPREHENSIVE REINTEGRATION ASSISTANCE FOR WOMEN WITH FEMALE GENITAL FISTULA: INTERVENTION PILOTING
REFNo: SS890ES
Aim 1: To understand the feasibility and acceptability of a pilot reintegration program for female genital fistula.
Aim 2. To assess the acceptability of the pilot reintegration intervention to patients, intervention implementors.
Aim 3. To assess the preliminary effectiveness of the pilot reintegration intervention.
|
Kampala, MULAGO
,
|
Uganda |
2021-06-24 |
2024-06-24 |
40 (30 women to participate in the intervention and indepth interview plus 10 stake holders |
Women aged 18 years and above or considered emancipated minors under Ugandan law who are undergoing genital fistula surgery. |
U.S. Eunice Shriver Kennedy National Institute of Child Health and Development. |
Social Science and Humanities |
Clinical Trial |
Non-degree Award |
|
Lukia Namaganda Hamid
ID:
|
Malnutrition as a probable predictor of mortality in cerebral palsy (CP), and the effect of positive deviance and parent facilitator training strategies to malnutrition and caregiving among children and adolescents with CP in the Iganga, Mayuge and Bugweri rural districts of eastern Uganda
REFNo: HS1427ES
Specific Objectives:
1. To assess mortality and whether malnutrition is one of the predictors among a population based sample of children and adolescents with cerebral palsy the Iganga Mayuge-Health and Demographic Surveillance Site (IM-HDSS), Uganda
2. To assess the difference in the change in nutritional status in 2015 and 2019 among children with CP compared to their age and sex matched controls without CP at the IM-HDSS, Uganda.
3. To explore positive and negative nutrition practices among caregivers of well-nourished and under-nourished children with cerebral palsy respectively at the IM-HDSS, Uganda.
4. To determine the difference in the effectiveness of the positive deviance strategy and parent facilitator trainings on CP child and adolescent malnutrition and caregiving within the Iganga, Mayuge and Bugweri districts, Uganda.
|
Iganga,
Mayuge,
|
Uganda |
2021-09-29 |
2024-09-29 |
126 for the RCT |
Caregivers of children and adolscents with Cerebral aged 2-21 years old |
Cerebral Palsy in Uganda Project (CURIE), Makerere University School of Public Health, Department of Epidemiology and Biostatistics |
Medical and Health Sciences |
Clinical Trial |
Degree Award |
|
Julius Okuni Boniface
ID: UNCST-2019-R000963
|
A MULTI-COUNTRY, SINGLE-BLINDED, PHASE 2 STUDY TO EVALUATE RAPID DETECTION SYSTEMS OF SARS-COV-2
REFNo: HS1425ES
1. To determine the clinical sensitivity of the test assays compared to the real-time RT-PCR-based method.
2. To determine the specificity of the test assays compared to the real-time RT-PCR-based method.
|
Kampala, Mulago
|
Uganda |
2021-06-16 |
2024-06-16 |
500 |
The age group will be adults from 18 years and above. The samples will be collected from archives at the Biorepository in the Department of Immunology and Molecular Biology, Makerere University. The samples will be from people from patients that had compl |
EDCTP |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Philippa Musoke
ID: UNCST-2021-R013523
|
ViiV 205858: Open-label access to dolutegravir for HIV-1 infected children
and adolescents completing IMPAACT Studies P1093 and P2019 Version 4.0 dated 10 Dec 2020
REFNo: HS1453ES
Primary
• To provide access to age appropriate formulations of dolutegravir (DTG), either as single entity DTG or as fixed dose combination (FDC) abacavir/dolutegravir/lamivudine (ABC/DTG/3TC), in an open-label protocol to eligible participant s who have completed the P1093 or P2019 parent studies.
Secondary
To assess any serious adverse events (SAEs) and any clinical or laboratory adverse events that lead to the discontinuation of IP (DTG or ABC/DTG/3TC FDC).
|
Kampala, Mulago
|
Uganda |
2021-08-20 |
2024-08-20 |
3 participants previously enrolled in P1093 at the MU-JHU Site |
Children aged 0-18 years who are formeerly participants in P1093 study at MU-JHU Site, both male and female and of any tribe as long as their caretakers/parents understand the language of consent. |
ViiV Health care Company |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Cissy Kityo
ID: UNCST-2021-R013663
|
Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in
Regions with SARS-CoV-2 Variants of Concern.
REFNo: HS1669ES
-To assess vaccine efficacy (VE) of COVID-19 mRNA vaccine to prevent
virologically-confirmed symptomatic COVID-19 starting 14 days after dose 2 in
adults who are at risk of severe COVID-19
-2. To assess vaccine efficacy (VE) of COVID-19 mRNA vaccine to prevent severe COVID-19 starting 14 days after dose 2 in adults who are at risk for severe COVID-19
-3. To assess safety and tolerability of COVID-19 mRNA vaccine in adults who are at risk of severe COVID-19
|
Wakiso, Ssabagabo
|
Uganda |
2021-08-20 |
2024-08-20 |
14,000 |
age ≥ 40 and at least one comorbidity known to be associated with severe COVID-19, 2) age ≥ 18 and pregnant, 3) age ≥ 18 and HIV-infected. |
South African Medical Research Council (SAMRC) Cape Town, South Africa. |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Clovice Kankya
ID: UNCST-2020-R010154
|
Capacitating One Health in Eastern and Southern Africa (COHESA)
REFNo: SS1482ES
To understand One Health performance, capacity, and bottlenecks within Uganda,To understand Current One Health Research and Innovation within Uganda,To understand One Health challenges, gaps and capacities within Uganda,
|
|
Uganda |
2022-10-27 9:26:54 |
2025-10-27 |
15 Key Informant Interviews, 15 people per workshop. |
Individuals and organizations contributing to One Health in both public and private sectors across Uganda. |
European Union |
Social Science and Humanities |
Clinical Trial |
Non-degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|
